{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:06:14Z","timestamp":1769853974788,"version":"3.49.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.lungcan.2014.06.002","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T21:39:08Z","timestamp":1402954748000},"page":"479-480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis"],"prefix":"10.1016","volume":"85","author":[{"given":"Chou-Han","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Tzer","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Wen","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Chi","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2014.06.002_bib0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/JTO.0b013e3182773f21","article-title":"Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors","volume":"8","author":"Lee","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2014.06.002_bib0010","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","article-title":"Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy","volume":"7","author":"Morris","year":"2012","journal-title":"J Thorac Oncol."},{"key":"10.1016\/j.lungcan.2014.06.002_bib0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.lungcan.2012.03.002","article-title":"Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group","volume":"77","author":"Umemura","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2014.06.002_bib0020","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","article-title":"Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer","volume":"13","author":"Grommes","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.lungcan.2014.06.002_bib0025","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1470-2045(12)70087-6","article-title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b\/3 randomised trial","volume":"13","author":"Miller","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2014.06.002_bib0030","first-page":"3000","article-title":"Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer","volume":"119","author":"Regales","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.lungcan.2014.06.002_bib0035","unstructured":"Horn L, Groen H, Smit E, Janjigian Y, Fu Y, Wang F, et al. Activity and tolerability of combined EGFR targeting with afatinib (BIBW 2992) and cetuximab in T790M+ NSCLC patients. Presented at the 14th World Conference on Lung Cancer, July 3-7, 2011, Amsterdam, the Netherlands. (abstr O19.07)."},{"key":"10.1016\/j.lungcan.2014.06.002_bib0040","first-page":"482s","article-title":"Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib","volume":"Suppl. 29","author":"Janjigian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2014.06.002_bib0045","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2009.26.7278","article-title":"Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors","volume":"28","author":"Yap","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2014.06.002_bib0050","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00066-010-2153-y","article-title":"Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC)","volume":"186","author":"Rades","year":"2010","journal-title":"Strahlenther Onkol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500214002608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500214002608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T10:20:35Z","timestamp":1538562035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500214002608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0169500214002608"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2014.06.002","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2014.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}